Other Development Activities. Constar, Inc. acknowledges that the Crown Entities currently undertake, and may undertake in the future, various research and development activities for other businesses. Subject to Sections 6 and 9, nothing in this Agreement shall be construed to prohibit the Crown Entities from continuing to undertake any such activities; provided, that nothing in this Section 11 shall relieve Crown of its obligations under the Non-Competition Agreement, dated as of the date hereof, between Crown and Constar.
Other Development Activities. Subject to the terms and conditions herein, with respect to each Licensed Product for which the Pre-Clinical Program is successfully completed as determined by the JDT, PTI shall be solely responsible for and shall use reasonable commercial efforts to conduct, as it deems appropriate or useful in its discretion in accordance with its obligations hereunder, all non-clinical and other work not included in the Pre-Clinical Program Plan to the extent required for Product Registration for such Licensed Product including [* * *]. Notwithstanding anything herein to the contrary, DURECT shall be solely responsible for all initial and subsequent [* * *] with respect to each Licensed Product during the Term of the Agreement in accordance with specifications as are determined by the JDT, and PTI shall reimburse to DURECT all DURECT Research Expenses associated with such [* * *] activities in accordance with the procedures set forth in Section 2.3(a) and (b) above with respect to DURECT’s Pre-Clinical Program activities; provided, however, if DURECT is unable to perform or fails to carry out any such [* * *], then PTI (itself or through Third Parties) shall have the right to perform such [* * *]. [* * *]. Accordingly, PTI shall provide to DURECT from time to time, under confidence, information in PTI’s possession or control reasonably necessary for DURECT to perform such [* * *] or any other development activity required to be performed by DURECT hereunder.
Other Development Activities. In the event that any additional studies are necessary in the Territory to support Regulatory Approval of the Lead Product by either the FDA or the CFDA, the Parties shall amend the Development Plan to reflect such additional studies (subject to Section 3.1(e)). For any such additional studies, Zai shall be responsible for [*] of Patient-Related Costs in the PRC; provided, that [*].
Other Development Activities. Except for the Development activities contemplated by Section 4.1, and subject to compliance with the provisions of the other foregoing Sections of this Article 4, all Development related to the Products or otherwise may be conducted by the Parties as they see fit and in their sole discretion, provided, however, that each Party shall provide to the other (a) information regarding any protocols for any clinical studies such Party may propose to carry out, and such Party shall consider in good faith any comments received from the other Party with respect to such protocols and clinical studies, and (b) copies of all substantive or material information with respect to its and its Third Party licensees or sublicensees Development activities for products that correspond to the Product, including clinical data compiled with respect to such products and all information and data filed with any Regulatory Authority relating to such products, as soon as reasonably practicable after such information, data or results become available or compiled, including any drafts and final versions of any study reports (the “Additional Development Data”). Aptalis shall have the exclusive right to use the Additional Development Data created by or on behalf of Strakan (or any portion thereof) solely to the extent necessary for Developing, Commercializing or Manufacturing the Product (and, for the sake of clarity, for no other pharmaceutical product) in or for the Territory during the Term, and shall have the right to grant sublicenses. Strakan shall have the exclusive right to use the Additional Development Data * Confidential treatment requested. created by or on behalf of Aptalis (or any portion thereof) solely to the extent necessary for Developing, Commercializing or Manufacturing the Product (and, for the sake of clarity, for no other pharmaceutical product) outside the Territory including the right to make or have made the Product in the Territory solely for the purpose of supplying its customers or those of its licensees outside the Territory and shall have the right to grant sublicenses. Subject to this Section 4.7, the Parties agree to exchange information related to any planned, in-progress and/or completed clinical studies that may be relevant to the other Party’s Development activities, including information with respect to Phase 4 Studies.
Other Development Activities. For the three (3)-year period of time beginning within the first calendar quarter of 2006 and ending three (3) years thereafter, PFIZER shall pay to XXXXX no less than [***********************************] per year for the development work to be specified in the Xxxxx Work Plan; any amounts in excess of a total of [**********] for such development work must be mutually agreed to by the parties. The Xxxxx Work Plan could include, without limitation, preclinical, clinical, biomarker work or other similar activities with respect to the Compound and will include the budget and deliverables for the activities to be conducted by XXXXX. The Xxxxx Work Plan will be updated, as appropriate, to reflect material changes and submitted to the Development Committee for approval as described in Section 4.5(a) Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. below. PFIZER shall pay to XXXXX [*******************] of the budgeted amount for each project or work activity prior to the commencement of such project or work activity and [*******************] of the budgeted amount upon the completion of the deliverable for each such project or work activity. If the scope or resources required for a deliverable changes materially during the course of the development activities, XXXXX will promptly notify the Development Committee, and the Development Committee will work, in good faith, to modify the Xxxxx Work Plan or adjust the budget, as appropriate.
Other Development Activities. In addition to the marketing and development activities described above, two additional development activities are anticipated to be pursued under this Agreement, as follows:
Other Development Activities. Prior to the commencement of other development activities, the parties will amend this Agreement to set forth the fee and revenue sharing arrangements applicable thereto.
Other Development Activities. (a) During the Development Period, MRP (either directly, and/or through Development Manager) shall cause to be undertaken by the appropriate parties, such as the Design Professional, construction contractors, service contractors or other Persons, all other activities which are reasonably required to prepare the Property for commencement of Vertical Construction within thirty (30) days after the Members approve such commencement of Vertical Construction (or commencement of Vertical Construction is otherwise authorized pursuant to this Article 4). All such matters shall be subject to the prior written approval of Investor, which approval shall not be unreasonably withheld, conditioned or delayed.
Other Development Activities. (a) Pre-Clinical Development. Terns shall have the right to conduct any pre-clinical studies to generate and obtain Data that is reasonably useful for the Development of any Licensed Product in the Terns Territory, provided that Terns shall promptly amend the Development Plan to include such pre-clinical studies and submit such amendment to the JSC for review.
Other Development Activities. With regard to all clinical and preclinical studies and other activities under the PDP Development Plan, other than the ACADIA Studies, the PDP Development Plan shall specify which Party shall be the Responsible Party with respect to conducting such studies and activities with oversight by the Development Committee. The PDP Development Plan shall also specify which Party shall be the Responsible Party with respect to conducting CMC studies and technology transfer for the manufacture and supply of the active pharmaceutical ingredient for Product and finished Product for the prevention or treatment of PDP in the Territory with oversight by the Development Committee, and the Budget for such activities. Whether BLS or ACADIA is the Responsible Party for conducting studies or other activities under the PDP Development Plan, except as otherwise provided in this Section 4.4(a) or in Section 4.4(b) or 4.4(c), BLS shall be responsible for funding all studies (other than the ACADIA Studies, with the exception of any such studies where the Parties have mutually agreed under the PDP Development Plan and applicable Budget to share costs) and other activities under the PDP Development Plan and all studies and other activities for obtaining Marketing Approval of Product in the Field in Canada, including but not limited to the CMC studies, safety and drug interaction studies and technology transfer activities, in accordance with Section 4.8(a)(i). […***…].
